Straits Times Index
3,084.70 +18.76 (+0.61%) S&P 500
4,554.89 +4.46 (+0.10%) Dow
35,416.98 +83.51 (+0.24%) Nasdaq
14,281.76 +40.73 (+0.29%) Bitcoin USD
38,243.26 +1,086.68 (+2.92%) CMC Crypto 200
790.02 +25.33 (+3.31%)
Bayer Aktiengesellschaft (BAYN.DE)
| Previous close | 30.56 |
| Open | 30.33 |
| Bid | 30.59 x 28400 |
| Ask | 30.61 x 2100 |
| Day's range | 30.22 - 31.03 |
| 52-week range | 30.22 - 65.66 |
| Volume | |
| Avg. volume | 3,316,951 |
| Market cap | 30.077B |
| Beta (5Y monthly) | 1.16 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.74 |
| Earnings date | 08 Nov 2023 |
| Forward dividend & yield | 2.40 (7.85%) |
| Ex-dividend date | 02 May 2023 |
| 1y target est | 51.20 |
- Financial Times
Bayer chief blames thin drug pipeline on ‘years of under-investment’
Bayer’s chief executive has blamed an “old chemistry mindset” and a chronic lack of investment in research by his predecessors for a thin drug pipeline that has dragged down the group’s share price. Bayer last week abandoned a trial of blood-thinner asundexian after it did not work as hoped to treat heart disease. The setback over a drug that was supposed to generate up to €5bn in annual sales at its peak caused Bayer’s already struggling stock to fall 18 per cent in a day.
- Financial Times
Bayer drug setback adds to new CEO’s problems
Halted trial of prospective blockbuster treatment follows latest US legal blow over weedkiller Roundup
ReutersExclusive-Bayer holds call with bond investors after raft of bad news
(Reuters) -Bayer held a call with investors on Monday after a raft of bad news led some of them to question whether the German group had been upfront about its prospects ahead of a $5.75 billion bond issuance, three sources familiar with the situation said on Wednesday. The bad news prompted some bond investors to question whether Bayer should sweeten the terms of the deal or outright pull it, one of the sources said. The drug-to-pesticides group priced the investment grade bond on Thursday last week, with the deal closing on Tuesday.
